Laboratory/Clinical Translational Research
Expression of p57/Kip2 Protein in Hepatocellular CarcinomaIto Y.a,b · Takeda T.a · Sakon M.c · Tsujimoto M.d · Monden M.c · Matsuura N.b
aDepartment of Surgery, Osaka Seamen’s Insurance Hospital, bDepartment of Pathology, School of Allied Health Science, Osaka University Faculty of Medicine, cDepartment of Surgery II, Osaka University Medical School, and dDepartment of Pathology, Osaka Police Hospital, Osaka, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Evaluation of the biological character of carcinomas requires understanding of cell cycle regulators. In the present study, we investigated the expression of p57 (Kip2) in 90 hepatocellular carcinomas and 66 noncancerous lesions. The average p57 labeling index in noncancerous lesions was 72.3 ± 19.7. The labeling index significantly decreased (p < 0.0001) in hepatocellular carcinoma (54.9 ± 19.7). It was significantly lower in hepatocellular carcinoma cases with high biological aggressiveness such as advanced stage (p = 0.0041), poor differentiation (p < 0.0001), larger size (p = 0.0400), portal invasion (p < 0.0001), satellite tumor (p = 0.0023), high proliferating activity (p = 0.0002) and cyclin D1 overexpression (p = 0.0416). Furthermore, cases with low p57 expression showed worse outcomes for disease-free survival in univariate analysis (p = 0.0235), although p57 expression could not be recognized as an independent prognostic factor. These findings suggest that p57 contributes to the downregulation of cell proliferation and to the progression of hepatocellular carcinoma.
© 2001 S. Karger AG, Basel
Beasley RP, Hwang L-Y, Lin C-C, Chien C-S: Hepatocellular carcinoma and hepatitis B virus. Lancet 1981;ii:1129–1133.
- Uwaifo AO, Bababunmi EA: Liver carcinogenesis in tropical Africa. IARC Sci Publ 1984;63:59–88.
Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1980;87:6547–6549.
- Sasaki K, Murakami T, Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579–584.
- Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Monden M: Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999;81:747–751.
- King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, Wu LH, Wu CW, Lui WY: Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:273–279.
- Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90–99.
- Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N: Expression and prognostic roles of cyclin dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000;59:68–74.
- Xiong Y, Hannon GI, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701–704.
- Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27/Kip 1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9–22.
- Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639–649.
Liver Cancer Study Group of Japan: The general rule of the clinical and pathological study of primary liver cancer, ed 3. Tokyo, Kanehara Press, 1992.
- Matsumoto M, Furihata M, Ohtsuki Y, Sasaguri S, Ogoshi S: Immunohistochemical characterization of p57/KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res 2000;20:1947–1952.
- Federsdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O’Hara MJ, Lu X: High level expression of p27Kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380–6385.
- Hui A-M, Cui X, Makuuchi M, Li X, Shi Y-Z, Takayama T: Decreased p27kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 1999;30:1167–1173.
- Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y: Characterization of the human p57KIP2 gene: Alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 1996;97:625–631.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.